Physician profile
Anthony J Cusano
NPI 1205944089
$3,428.63
in general payments reported to CMS, 2019-2025
28 companies · $26.42 in 2025
The $26.42 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $700 · 2021: $785 · 2022: $529 · 2023: $656 · 2024: $80.88 · 2025: $26.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.54 |
| Education | $107.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $437.53 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $423.69 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $309.88 | 2019-2023 | Jardiance |
| Mallinckrodt Hospital Products INC. | $265.38 | 2021-2023 | Acthar |
| Otsuka America Pharmaceutical, INC. | $192.53 | 2019-2023 | Jynarque |
| Akebia Therapeutics INC | $172.46 | 2019-2023 | Auryxia |
| Vifor Pharma, INC. | $170.91 | 2019-2023 | Veltassa |
| Amgen INC. | $166.63 | 2019-2024 | Krystexxa |
| Genzyme Corporation | $164.59 | 2019-2023 | |
| Medtronic USA, INC. | $128.66 | 2020 | |
| Travere Therapeutics, INC. | $119.62 | 2019-2024 | |
| Baxter Healthcare | $102.90 | 2021-2025 | Renal - Pd |
| Bayer Healthcare Pharmaceuticals INC. | $91.32 | 2021-2024 | |
| Ultragenyx Pharmaceutical INC. | $89.77 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $84.63 | 2019-2023 | Ultomiris |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $76.99 | 2020 | |
| Fresenius USA Marketing, INC. | $64.21 | 2019-2023 | Velphoro |
| Smith+Nephew, INC. | $57.91 | 2023 | Redapt, Or3o Dual Mobility |
| Glaxosmithkline, LLC. | $56.59 | 2022-2023 | Benlysta, Jesduvroq |
| Amag Pharmaceuticals, INC. | $54.21 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $50.73 | 2022-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $33.29 | 2023 | Tarpeyo |
| Nxstage Medical, INC. | $24.03 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.33 | 2020 | |
| Daiichi Sankyo INC. | $18.58 | 2019 | |
| Horizon Therapeutics Plc | $18.54 | 2021 | |
| Pfizer INC. | $18.39 | 2023 | |
| Merck Sharp & Dohme LLC | $15.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Cusano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.